Sharl Azar, MD
The December 2023 FDA approval of the first two gene therapies to treat sickle cell disease (SCD) was a giant step forward in managing the most common and clinically significant inherited blood disorder across the United States. However, as approved centers prepare to begin offering exagamglogene autotemcel (exa-cel; Casgevy, Vertex Pharmaceuticals) and lovotibeglogene autotemcel (lovo-cel; Lyfgenia, Bluebird Bio), many questions remain about cost, insurance coverage